SCHEMBL4471509

SCHEMBL4471509

COc1cc2c(Oc3ccc(NC(=O)NCCC(C)(C)C)cc3)ccnc2cc1OCCCN1CCC(c2ccccc2)CC1

nearest known ligand 0.60

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
MET P08581 16/20 0.60
PDGFRA P16234 2/20 0.58
EGFR P00533 1/20 0.57
KDR P35968 2/20 0.55
FGFR2 P21802 1/20 0.54
HDAC1 Q13547 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4489289 0.97 PDGFRA (0.58) METPDGFRAEGFRKDRFGFR2
SCHEMBL4462008 0.91 PDGFRA (0.61) METPDGFRAEGFRKDRFGFR2
SCHEMBL4485417 0.91 PDGFRA (0.61) METPDGFRAEGFRKDRFGFR2
SCHEMBL4473158 0.91 MET (0.61) METPDGFRAEGFRKDRFGFR2
SCHEMBL4472236 0.90 FGFR2 (0.66) METPDGFRAEGFRKDRFGFR2
SCHEMBL4480530 0.90 FGFR2 (0.66) METPDGFRAEGFRKDRFGFR2
SCHEMBL4482687 0.89 PDGFRA (0.61) METPDGFRAEGFRKDRFGFR2
SCHEMBL4470936 0.89 PDGFRA (0.63) METPDGFRAEGFRKDRFGFR2
SCHEMBL4471915 0.89 PDGFRA (0.63) METPDGFRAEGFRKDRFGFR2
SCHEMBL13936890 0.89 FGFR2 (0.57) METPDGFRAKDRFGFR2HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US claimed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-20050049264-A1 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2005-03-03 US disclosed
EP-1447405-A1 QUINOLINE OR QUINAZOLINE DERIVATIVES INHIBITING AUTO-PHOSPHORYLATION OF FIBROBLAST GROWTH FACTOR RECEPTORS KIRIN BEER KABUSHIKI KAISHA (JP) 2004-08-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049264-A1 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors FGFR1, FGFR2, FGFR3 MET 6/4885PDGFRA 372/4885EGFR 16/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.